Best Medical Group Management Association Podcasts (2025)

1
Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and ... 19:38

Play Pause

18h ago19:38

19:38

In this week's episode, we’ll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identifi…

1
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets 41:28

5d ago41:28

41:28

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma. See the full review series on high risk lymphoma…

1
Re-Release of AFSPA Talks Support for LGBTQ+ Youth 52:48

8d ago52:48

52:48

Happy Pride! For this week's episode, we wanted to share some information that would be helpful to members who have contacted us with questions about care and support for their children who are exploring their identities. We went back into our archive, and we're sharing an episode with Alyssa Clayden, PhD, LICSW, from the Truman Group that we origi…

1
A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset 20:30

12d ago20:30

20:30

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-c…

1
Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma 9:47

14d ago9:47

9:47

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, invol…

1
Alex Jenkins from NestEggs Retirement Plan Services 15:52

18d ago15:52

15:52

Send us a text In this episode, we welcome Alex, a partner at NestEggs, to discuss how their firm supports privately held businesses and trade associations with comprehensive retirement plan solutions. Alex shares his journey from medical device sales to becoming an investment advisor and details NestEggs’ unique approach as one of the last private…

1
How I Treat Series on Geriatric Hematology 17:19

19d ago17:19

17:19

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.By American Society of Hematology

1
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance 16:06

19d ago16:06

16:06

In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences …

1
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE 19:46

26d ago19:46

19:46

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: …

1
Press Release Audio Transcript: Concourse Benefits launches new Affinity Network Platform at Web Summit Vancouver 3:46

1M ago3:46

3:46

Send us a text Concourse Benefits is transforming how business organizations, like chambers of commerce and trade associations, can deliver more value to their members. Today, the company announced its investor proposal and valuation analysis, highlighting a funding round to accelerate platform development and rapid market expansion. Concourse Bene…

1
How I Treat Transfusion Medicine (part 2) 33:57

1M ago33:57

33:57

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George. Find the full published review series in Volume 145 Issue 20 of Blood Journal.By American Society of Hematology

1
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19 ... 20:57

1M ago20:57

20:57

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acut…

1
AFSPA Talks The Truman Group 31:38

1M ago31:38

31:38

May is Mental Health Awareness Month. The recent changes to the federal workforce and the uncertainty that continues for many have resulted in mental health concerns for many with ties to federal employment - employees and family members alike. Stress, anxiety, fear, anger, and worry are all understandable reactions, but you do not have to face the…

1
How I Treat Transfusion Medicine (part 1) 32:12

1M ago32:12

32:12

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RB…

1
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT 18:15

1M ago18:15

18:15

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differe…

1
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease 19:58

2M ago19:58

19:58

In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickl…

1
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature 18:12

2M ago18:12

18:12

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffu…

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ... 19:06

2M ago19:06

19:06

In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…

1
AFSPA Talks Chronic Care Management 26:27

2M ago26:27

26:27

In this episode of AFSPA Talks, we continue our conversation from Annual Meeting about weight loss, cardiovascular health, and diabetes management. Today's focus is on Chronic Care Management Programs. To tell us more about those programs, we have Grace Silverio from Teladoc Health. For more information about the Chronic Care Management Programs av…

1
How I Treat Myeloproliferative Neoplasms 38:36

2M ago38:36

38:36

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat se…

1
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL 18:49

2M ago18:49

18:49

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options…

1
Campaign Compass on Concourse Benefits with Nancy Cooke 14:50

2M ago14:50

14:50

Send us a text Learn about Campaign Compass in this podcast interview with Founder, Nancy Cooke. Connect with Nancy on her LinkedIn Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the o…

1
AFSPA Talks Lifestyle and Condition Coaching 27:52

2M ago27:52

27:52

This month, AFSPA Talks takes a look at some of the support programs available to members of the Foreign Service Benefit Plan. To begin, we'll discuss the Lifestyle and Condition Coaching (LCC) program with Dr. Vivian Ogueli and Leah Perry, RN. They offer details on how to complete a health risk assessment (HRA) and earn $75 in wellness incentives,…

1
Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed ... 20:59

2M ago20:59

20:59

In this week's episode we’ll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refract…

1
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL 15:26

3M ago15:26

15:26

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, …

1
Blood Bonus Episode: What is a Blood group? 14:59

3M ago14:59

14:59

In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-ne…

1
Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle ... 19:16

3M ago19:16

19:16

In this week's episode, we’ll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles: Itacitinib…

1
AFSPA Talks Medicare and the FEHB in 2025 1:05:14

3M ago1:05:14

1:05:14

In this podcast episode, AFSPA CEO, Kyle Longton provides a comprehensive overview of how Medicare and the Federal Employee Health Benefits (FEHB) program work together. Learn about each part of Medicare - A, B, C, and D - and what factors you should consider when deciding whether to enroll in Part B. Please note: this presentation addresses only h…

1
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis 19:07

3M ago19:07

19:07

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome…

1
Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL 21:28

3M ago21:28

21:28

In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL. Featu…

1
Co-Founder Story with Colin Schmidt 11:49

3M ago11:49

11:49

Send us a text Colin Schmidt's LinkedIn: https://www.linkedin.com/in/colin-schmidt/ Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concourse Benefits Platf…

1
Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk 17:48

4M ago17:48

17:48

In this week's podcast, a potential new therapeutic target in beta-thalassemia. The E3 ubiquitin ligase AMBRA1 promotes autophagic clearance of free alpha-globin. Researchers describe mutations in the AMBRA1 gene that impair this clearance, exacerbating ineffective erythropoiesis and disease severity. After that: targeting MYD88 mutations. Lasaloci…

1
Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal ... 19:28

4M ago19:28

19:28

In this week's episode we’ll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies. Featured Articles: Approaching Hyperca…

1
Review Series on a Quarter Century of TKIs in CML 33:05

4M ago33:05

33:05

In this Review Series episode Reflections on a Quarter Century of TKIs in CML introduced by Associate Editor Dr. Jason Gottlieb, we’ll hear from contributing authors Drs. Brian Drucker, Francois Guillot, Tim Hughes and Michael Deininger, as they discuss how CML treatment has been impacted since the introduction of tyrosine kinase inhibitors 25 year…

1
SquareStack in Concourse Benefits with Bill Furlong 22:16

4M ago22:16

22:16

Send us a text Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concourse Benefits Platform, hosted by Marc Palud, one of the Co-Founders and Chief Marketing…

1
A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes 19:09

4M ago19:09

19:09

In this week's episode, we'll hear about a “belt and suspenders” approach to paroxysmal nocturnal hemoglobinuria, or PNH. We’ll review long-term efficacy data for danicopan—an oral complement factor D inhibitor recently approved as an add-on to C5 inhibitor therapy. After that: researchers show how oral pathogens may exacerbate chronic graft-versus…

1
Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells 23:14

4M ago23:14

23:14

In this week's episode we’ll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells. Feature…

1
Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor 31:38

4M ago31:38

31:38

In this Review Series episode on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor introduced by Dr. Thomas Ortel, we’ll hear from contributing authors Drs. Ben Samuelson Jones, Mac Monroe and Peter Lenting as they discuss how the functional roles of these 3 proteins are interconnected. Click here to view the complete…

1
VirtualE on Concourse Benefits with guest Marco Macrì 4:06

4M ago4:06

4:06

Send us a text Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concourse Benefits Platform, hosted by Marc Palud, one of the Co-Founders and Chief Marketing…

1
Privacy Pillar for Concourse Benefits Users with guest Rinto John 5:43

4M ago5:43

5:43

Send us a text Automate trust and transparency with a privacy-by-design platform. Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concourse Benefits Platfor…

1
Marketplace Vendor Episode: Cybersecurity Posture Assessments, with Hernan from POPP3R Cybersecurity 13:47

5M ago13:47

13:47

Send us a text Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concourse Benefits Platform, hosted by Marc Palud, one of the Co-Founders and Chief Marketing…

1
Querri 8:21

5M ago8:21

8:21

Send us a text Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concourse Benefits Platform, hosted by Marc Palud, one of the Co-Founders and Chief Marketing…

1
Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor 18:41

5M ago18:41

18:41

In this week's episode we'll learn about asciminib plus dasatinib in Philadelphia chromosome-positive acute leukemia. In a phase 1 study, combining two tyrosine kinase inhibitors with distinct mechanisms of action had encouraging activity in patients with de novo disease. After that: new research demonstrates that the iron exporter ferroportin cont…

1
First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia 20:37

5M ago20:37

20:37

In this week's episode we’ll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia. Featured Articles…

1
AFSPA Talks Japan Pilot Program 24:48

5M ago24:48

24:48

Two years ago, access to on-base care for Department of Defense civilians changed, which had a particular impact on those living and working in Japan. Since then, DoD leaders have been working on a program to support the needs of civilian employees in Japan. That program launched at the beginning of this year, and we wanted to know more about how i…

1
Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex 19:02

5M ago19:02

19:02

In this week's episode we'll learn about C3-targeted therapy in autoimmune hemolytic anemias. Based on results of an open-label, phase 2 study, pegcetacoplan was well-tolerated, with encouraging efficacy, particularly in patients with cold agglutinin disease. After that: Venetoclax sensitivity testing to predict AML response. In a significant step …

1
Review Series on Globin Disorders 23:17

5M ago23:17

23:17

In this Review Series episode on Globin Disorders introduced by Drs. Thomas Coates and Irene Roberts, we’ll hear from Dr. Douglas Higgs and Dr. Mitchell Weiss as they address advances in our understanding of globin gene biology. Click here to view the complete Review Series featured in Volume 144 Issue 8 of Blood.…

1
AFSPA Talks Tips for New Members 21:31

5M ago21:31

21:31

With Open Season over and a new year underway, hosts Kyle Longton and Maddie Norton use the first episode of 2025 to provide tips for the 10,000 new FSBP members and the more than 100,000 continuing members. Here are links to the resources they mentioned during this episode: AFSPA Website: www.afspa.org Online Portals for FSBP Members (including de…

1
Co-Founder Story with Susan Ellender 14:25

5M ago14:25

14:25

Send us a text Connect with Susan on LinkedIn at https://www.linkedin.com/in/susan-ellender-222b2365/ Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the latest insights from the official podcast for the Concou…

1
Co-Founder Story with Marcie O'Dwyer 16:38

5M ago16:38

16:38

Send us a text Connect with Marcie on LinkedIn at: https://www.linkedin.com/in/marcie-o-dwyer-b29197129/https://www.linkedin.com/in/marcie-o-dwyer-b29197129/ Conversations on all things benefits including trends, innovations, new technologies, and idea to help associations create more value for members, employees, and their families. Catch all the …